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Background: Non-alcoholic fatty liver disease (NAFLD) is becoming a public 
health problem worldwide and using microalgae is a new approach on its treat-
ment. The aim of this study was to investigate the effect of Chlorella vulgaris 
supplementation on liver enzymes, serum glucose and lipid profile in patients 
with NAFLD.  
Methods: This double-blind  randomized placebo-controlled clinical trial was 
conducted on 60 NAFLD patients from specialized clinics of Tabriz University 
of  Medical  Sciences  from  December  2011  to  July  2012.  The  subjects  were 
randomly allocated into 2 groups: 1) “intervention” (n=30) received 400 mg/day 
vitamin E plus four 300 mg tablets of Chlorella vulgaris and, 2) “placebo” (n=30) 
received 400 mg/day vitamin E and four placebo tablets per day for 8 weeks. 
Weight, liver enzymes and metabolic factors were assessed in fasting serum and 
dietary data was collected at baseline and end of the study. 
Results: Weight, liver enzymes, fasting blood sugar (FBS) and lipid profile de-
creased significantly in both groups (P<0.05). The differences in weight, ALP 
and FBS between the two groups were statistically significant (P=0.01, P=0.04 
and P=0.02, respectively).  
Conclusion: C. vulgaris seems to improve FBS and lipid profile and therefore 
could be considered as an effective complementary treatment in NAFLD. 
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Introduction 
 
Obesity  is  a  complex  disorder  that  be-
coming  a  public  health  problem  in  the 
worldwide.
1  The  increase  of  obesity  has 
played  an  important  role  in  the  increasing 
prevalence of nonalcoholic fatty liver disease 
(NAFLD) as well.
2 It is characterized by fat 
accumulation  in  exceeding  5-10%  hepato-
cyte.
3 NAFLD is considered as an emerging 
epidemic in many countries.
4 The prevalence 
of NAFLD is estimated 10-35% in general 
population
5 and 5-30% in Asia.
6 It encom-
passes a spectrum of disease ranging from 
steatosis,  non-alcoholic  steatohepatitis 
(NASH),  fibrosis,  cirrhosis  and  hepatocyte 
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carcinoma.
7  Although  health  promotion 
strategies regarding lifestyle factors such as 
diet therapy, increasing physical activity, sur-
gical intervention and pharmacotherapy are 
recommended for NAFLD treatment,
8 there 
is  no  consensus.
9  However,  sometimes 
weight loss is not achievable without using 
supplements  for  controlling  food  intake.
10 
One of the weight loss supplements is chlo-
rella vulgaris (C. vulgaris) as a functional food 
supplements.
11 
Chlorella – a unicellular green microalgae-  
is popular as functional food and alternative 
medicine  in  worldwide,  particularly  in 
Asia.
12,13 It is used  as a dietary  supplement 
because of providing high amount of amino 
acids (apart from methionine and tyrosine), 
minerals, vitamins, fiber and bioactive com-
pounds.
11,14 Many studies have reported cer-
tain  beneficial  physiological  effects  against 
oxidation, cataract, bacterial and viral infec-
tion,  and  inflammation  as  well  as  weight 
loss, hypoglycemic and hypocholesterolemic 
effects in rats, mice and other laboratory an-
imals.
15,16 However, there are limited clinical 
trials particularly in human.
17 Lee et al. re-
ported  that  chlorella  containing  diets  in-
creased total amount of excreted feces and 
lipids  and  subsequently,  lowered  liver  and 
serum total lipids, triglycerides (TG) and to-
tal cholesterol (TC) without any significant 
reduction in alanin aminotransferase (ALT) 
and  aspartate  aminotransferase  (AST)  con-
centrations  in  animals.
18  In  a  clinical  trial, 
consumption  of  chlorella  tablets  for  16 
weeks led to activation of insulin signaling 
pathways in subjects who were at risk of life-
style –related diseases and therefore resulted 
in decreases in serum levels of fasting glu-
cose (FBS) and TC.
17 
Chlorella vulgaris, a strain of chlorella, has 
been  recently  studied.
18  There  is  evidence 
reporting  hypoglycemic  and  hypolipidemic 
effects of C. vulgaris.
19,20 For example, C. vul-
garis  significantly  decreases  serum  glucose 
and  improve  insulin  sensitivity  in  diabetic 
rats.
14 Indeed, C. vulgaris may be effective for 
the  prevention  of  dyslipidemia.
20  Supple-
mentation with C. vulgaris decreased weight, 
ALT,  AST  and  TG  levels  in  NAFLD  pa-
tients.
21 
There is no convincing evidence for hy-
poglycemic and hypolipidemic effects of C. 
vulgaris in NAFLD patients. As there are li-
mited evidence, e.g. RCTs and also human 
studies  indicating  the  health  beneficial  ef-
fects of C. vulgaris in NAFLD, therefore, this 
study was aimed to investigate the effect of 
C.  vulgaris  supplementation  on  Liver  en-
zymes,  serum  glucose  and  lipid  profile  in 
patients with NAFLD. 
 
Materials and Methods 
 
This double-blind, randomized controlled 
clinical  trial  was  carried  out  on  70  obese 
adult patients with NAFLD recruited from 
clinics of Tabriz University of Medical Sci-
ences  from  December  2011  to  July  2012. 
Sample size was determined based on prima-
ry information obtained from the study by 
Mizoguchi  et  al.  (2008)
17  for  high-density 
lipoprotein cholesterol (HDL-c). The study 
protocol was approved by the Ethics Com-
mittee of Tabriz University of Medical Sci-
ences and was registered in the Iranian Reg-
istry  of  Clinical  Trials  website 
(IRCT201202233320N7).   
Sample Size was computed 26 per group 
by considering α=0.05 and a power of 90%. 
This number was increased to 30 per group 
to  accommodate  the  anticipated  dropout 
rate.  
All participants underwent ultrasonogra-
phy  for  determining  fatty  liver  by  a  single 
sonographist. Echogenisity grading was per-
formed  using  Sonoace  X4  Medisio  (South 
Korea). NAFLD is defined by elevated liver 
enzymes (ALT greater than 31 mg/dl and 41 
mg/dl and AST greater than 31 mg/dl and 
47 g/dl in women and men , respectively) 
and  echogenicity  grading  of  the  liver  was 
based on Saverymuttu et al.
22 i.e. “mild stea-
tosis” as a slight increase in liver echogenic-
ity and exaggeration of liver and kidney echo 
discrepancy,  and  relative  preservation  of 
echoes  from  the  walls  of  the  portal  vein., 
“moderate  steatosis”  as  a  loss  of  echoes 
from the walls of the portal veins, particu-Ebrahimi-Mameghani et al.: The Effect of Chlorella vulgaris … 
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larly from the peripheral branches, resulting 
in a feature less appearance of the liver as 
well as a greater posterior beam attenuation 
and  a  greater  discrepancy  between  hepatic 
and renal echoes, and “severe steatosis” as a 
greater reduction in beam penetration, loss 
of echoes from most of the portal vein wall, 
inc.  the  main  branches  and  a  large  discre-
pancy between hepatic and renal echoes. 
Of totally 247 recruited patients, only 60 
confirmed NAFLD patients met the inclu-
sion criteria inc. aged 20-50 years from both 
genders, and BMI equal or over 30 kg/m
2. 
Patients with liver diseases such as Wilson
’ s 
disease,  autoimmune  liver  disease,  hemo-
chromatosis,  virus  infection  and  alcoholic 
fatty liver as well as those with hepatotoxic, 
lipid lowering, metformin consumption and 
antihypertensive  medication,  contraceptive 
and estrogen were excluded. 
The  aim  of  the  study  was  carefully  ex-
plained to the patients and their written in-
formed consent was obtained. Personal cha-
racteristics inc. demographic and disease his-
tory were obtained. Weight and height were 
measured  with  Seca  scale  (Hamburg,  Ger-
many) to the nearest 100 g and 0.5 cm, re-
spectively and BMI was estimated. Dietary 
data was collected using a three-day dietary 
record  and  averages  of  3-day  energy  and 
macro-nutrients intakes were analyzed using 
Nutritionist  IV  software.  A  self-reported 
questionnaire was used to estimate physical 
activity level.
23-25 
Patients were randomly allocated using a 
computer-generated  random  sequence  into 
two  groups;  “intervention”  and  “placebo”. 
The  subjects  were  randomly  allocated  into 
two  groups  “C.  vulgaris”  and  “placebo” 
groups.  As  vitamin  E  is  commonly  pre-
scribed for NAFLD patients,
25 therefore, all  
patients in both groups received vitamin E 
400  mg/d  plus  four  300  mg  tablets  of  C. 
vulgaris  (commercially  available  under  the 
name of ALGOMED® (Bioprodukte Prof. 
Steinberg  Produktions-  und  Vertriebs 
GmbH & Co KG,Germany) before break-
fast (1 tablet), lunch (2 tablets) and dinner (1 
tablet)  was  considered  as  C.  vulgaris  group 
while those in placebo group received 400 
mg/d vitamin E and four placebos per day 
for 8 weeks (Fig.1). The dose of C. vulgaris 
used  in  this  study  was  based  on  the  trial 
conducted already.
21 
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The placebo tablets supplied by School of 
Pharmacy, Tabriz University of Medical Sci-
ences, Iran were similar to C. vulgaris tablets 
in color and size. All participants were asked 
to maintain their usual lifestyle. Ten ml fast-
ing blood samples was taken from each sub-
ject and after serum separation was used for 
assessing serum ALT, AST, ALP, FBS and 
lipid profile (inc. TC, LDL-C, HDL-C and 
TG).  Liver  enzymes  and  metabolic  factors 
were  measured  by  International  Federation 
of Clinical Chemistry and Laboratory Medi-
cine  (IFCC)
23  and  enzymatic  colorimetric 
assay respectively. 
All statistical procedures were performed 
using SPSS software (ver. 17.0). Normality 
of  continuous  variable  was  tested  by  Kol-
mogorov-Smirnov  test.  Data  are  expressed 
as mean ± SD for normally distributed va-
riables.  Differences  in  mean  of  the  conti-
nuous  variables  between  the  two  groups 
were  tested  using  analysis  of  covariance 
(ANCOVA) for adjusting for baseline mea-
surements  and  covariates.  Changes  in  bio-
chemical  parameters over the  study  period 
were estimated by after intervention minus 
baseline  amount  was  done  using  paired  t-
test. P value less than 0.05 was considered 
statistically significant. 
 
Results 
 
Of totally 60 patients, 55 patients com-
pleted the study (n=29 and 26 for C. vulgaris 
and  placebo  groups,  respectively)  (Fig.1). 
General characteristics of the study subjects 
are listed in Table 1.  
There were no significant differences at 
baseline between the two groups in terms of 
age  (37.00±  7.45  yr  and  37.73±8.24  yr  in 
intervention and placebo group, respective-
ly), gender,  marrital status,  education level, 
physical activity and the severity of fatty liv-
er. The mean daily macronutrient and dietary 
fiber intakes were shown in Table 2. Dietary 
data assessment over the study showed no 
significant changes in total energy intake, fat, 
protein and dietary fiber over the study in 
both group. There was significant reduction 
in  carbohydrate  intake  in  C.  vulgaris  group 
(P=0.02). There were  no significant differ-
ences in the mean nutrient intakes between 
the two groups at baseline and also after 8 
weeks. 
The mean ± SD of biochemical factors 
before  and  after  intervention  are  shown  in 
Table 3. At the beginning of the study, the 
groups were similar based upon weight, liver 
enzymes, serum FBS and lipid profile.  
Weight  decreased  significantly  in  both 
groups (P<0.001). The mean weight change 
in the C. vulgaris group was significantly great-
er than the placebo group (P=0.001).  
Both group showed significant reductions 
in ALT and ALP levels after 8 week period 
(P<0.001). AST declined in C. vulgaris group 
(P<0.001)  while  AST  level  remained  un-
changed in the placebo group (P>0.05). After 
8  weeks  of  supplementation,  no  significant 
changes were observed in liver enzymes con-
centrations between the two groups (P>0.05).  
 
Table 1: Baseline characteristics of the NAFLD patients in each group 
 
† PAL assessed based on Johansson et al/‡ Fatty liver grading was based on Saverymuttu et al.  
Characteristic  C. vulgaris(n= 29) N (%)  Placebo(n= 26) N (%)  Sig. (Chi square) 
Male  15 (51.7)  15 (57.7)  0.788 
Married  27 (93.1)  23 (88.5)  0.659 
Less than high school  9(31)  14(53.8)   
Completed high school  14(48.2)  8(30.76)  0.870 
University certificate  6(20.68)  49(15.38)   
Physical Activity†       
     Inactive     11 (37.9)  11 (42.3)   
     Light activity  7 (24.1)  8 (30.8)  0.744 
     Moderate activity  11 (37.9)  7 (26.9)   
Severity of fatty liver‡       
     Mild  14(48.3)  17(65.4)   
     Moderate  13 (44.8)  8(30.8)  0.440 
     Severe  2(6.9)  1(3.8)   Ebrahimi-Mameghani et al.: The Effect of Chlorella vulgaris … 
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Table 2: Mean ± SD daily total energy and macronutrient intakes before and after intervention 
    C. vulgaris (n=29)  Placebo(n=26)  P** 
Energy (Kcal)  Before  1975±424  2008±584  0.81 
  After  1944±370  1969±550  0.84 
  MD (CI 95%)  -30(-72.69 to 11.24)  -39(-81.08 to 2.49)   
  P*  0.145  0.064   
Carbohydrate(g)  Before  291.1±83  248±94.9  0.079 
  After  264±70.3  248±70.3  0.409 
  MD (CI 95%)  50.8(108.38 to 210.17)  0.12(-48.3 to -21.02)   
  P*  0.02  0.996   
Dietary fiber (g)  Before  15.2±5.2±5.2  16.6 ±16.3  0.225 
  After  14.16±4.42  20.3±16.6  0.201 
  MD (CI 95%)  -1(-2.4 to .30)  3.6 (-3 to -10.3)   
  P*  0.642  0.272   
Protein (g)  Before  72.2±17.4  67.3±23.5  0.388 
  After  71.6±15.9  67.1±23.7  0.979 
  MD (CI 95%)  -0.5(-2.8 to 1.8)  -2 (-1.4 to 0.9 )   
  P*  0.642  0.621   
Fat (g)  Before  54.7±16.5  58,3±23.4  0.516 
  After  51.80±18.80  58±22.5  0.06 
  MD (CI 95%)  -2.9(-5 to 0.8)  -.0.32(-2.1 to 1.5)   
  P*  0.07  0.723   
*Paired t-test/**Independent t test 
 
 
Table 3: Mean ± SD biochemical factors before and after intervention 
    C. vulgaris (n=29)  Placebo(n=26)  P 
Weight (Kg)  Before  86.21±10.74  89.50±13.87  0.327b 
  After  82.60±11.5  87.34±13.33  0.01c 
  MD (CI 95%)  -3.60(-4.23 to -2.97)  -2.15 (-2.76 to -1.54)   
  Pa  <0.001  <0.001   
BMI (kg.m2)  Before  32.44±3.61  33.19±4.26  0.489b 
  After  31.09±3.82  32.41±4.24  0.01c 
  MD (CI 95%)  -1.35(-1.59 to 1.11)  -0.77(-1.59 to -1.11)   
  Pa  <0.001  <0.001   
ALT (IU/L)  Before  43.59±22.80  42.62±23.71  0.878b 
  After  30.38±18.32  36.88±22.83  0.154c 
  MD (CI 95%)  -13.20 (-18.68 to -7.73)  -5.73 (-47 to -2.42)   
  Pa  <0.001  0.01   
AST (IU/L)  Before  29.14±12.19  28.69±12.34  0.894b 
  After  21.93±9.01  25.62±10.6  0.188c 
  MD (CI 95%)  -10.80 (-29.04 to -12.75)  -7.68 (-21.33 to 14.58)   
  Pa  <0.001  0.07   
ALP (IU/L)  Before  188.59±55.31  194.15±70.21  0.744b 
  After  158.79±52.72  191.50±63.13  0.04c 
  MD (CI 95%)  -29.79 (-43.28 to -16.30)  -2.65(-8.44 to-6.83 )   
  Pa  <0.001  <0.001   
FBS (mg/dl)  Before  97.28±12.36  97.42±15.37  0.565b 
  After  89.31±10.93  95.96±14.17  0.02c 
  MD (CI 95%)  -7.96 (-11.21 to -4.71)  -1.46 (-4.69 to -1.77)   
  Pa  <0.001  <0.001   
TC (mg/dl)  Before  212.03±40.60  204.88±37.24  0.501b 
  After  186.59±3.99  192.35±33.81  0.821c 
  MD (CI 95%)  -25.44 (-35.10 to -15.79)  -12.53(-20.22 to -4.84)   
  Pa  <0.001  <0.001   
LDL-c (mg/dl)  Before  131.08±35.63  122.51±31.59  0.561b 
  After  110.92±28.37  112.51±31.59  0.825c 
  MD (CI 95%)  -20.16 (-30.40  to -9.92)  -10.17 (-19.31 to -1.02)   
  Pa  <0.001  <0.001   
HDL-c (mg/dl)  Before  41.59±8.36  43.58±10.65  0.442b 
  After  45.93±8.54  43.81±10.39  0.845c 
  MD (CI 95%)  4.34(1.19 to 7.49)  0.23(-2.94 to 3.40)   
  Pa  0.04  <0.001   
TG (mg/dl)  Before  178.86±8.36  169.73±81.14  0.694b 
  After  156.36±66.27  160.81±70.61  0.318c 
  MD (CI 95%)  -22.50 (-43.83 to -1.16)  -8.92(-26.15 to 8.30)   
  Pa  <0.001  <0.001   
ALT: -Alanin aminotransferase; AST: Aspartate aminotransferase ; ALP:Alkalin phosphatase ; FBS: Fasting blood 
sugar; TC: Total cholesterol; LDL-c: Low-Density lipoprotein; HDL: High- Density lipoprotein; TG: Triglycer-
ides; MD: Mean differences; CI: Confidence Interval/a : Paired t-test;b: Independent t test ;c: Based on Ancova 
adjusted for baseline values and carbohydrate intake Health Promotion Perspectives, Vol. 4, No. 1, 2014; P: 107-115 
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Both groups showed significant reduction 
in the serum glucose level after 8 week pe-
riod (P<0.001) and the mean change in glu-
cose  level  between  the  two  group  reached 
statistically significant level (P=0.02) i.e. the 
C.  vulgaris  group  had  more  reduction  than 
the placebo group. Serum TC, LDL-c, TG 
levels  decreased  significantly  (P<0.001) 
while HDL-c level increased (P=0.04) in the 
both groups. No significant changes in se-
rum lipid profile were observed between the 
two groups (P>0.05). 
 
Discussion 
 
This study has provided insights into the 
weight loss effect of C. vulgaris supplementa-
tion among NAFLD patients. In the present 
study, significant reductions were found in 
ALT  and  ALP  levels  in  both  groups  and 
AST declined in C. vulgaris group. Although 
there are limited studies examining the effect 
of chlorella on liver function, Lee et al.
18 had 
tested  different  diets  containing  5%  and 
10%  w/w  chlorella  compared  with  diet 
without  chlorella  on  liver  enzymes  in  rats 
and found that ALT and AST levels did not 
change after consumption of chlorella-con-
taining diets. Indeed, Panahi et al.
21 in a clini-
cal trial with C. vulgaris consumption (1200 
mg/day) for three months among NAFLD 
patients  showed  significant  reductions  in 
ALT and AST in C. vulgaris group vs. control 
group. The probable effect of chlorella on 
liver function could be due to its effect on 
weight.
26 To the best of our knowledge, the 
only study found to investigate the effect of 
chlorella (i.e. C. vulgaris) on liver enzymes as 
well as weight was Panahi et al. study.
21 They 
assessed the effect of metformin 750 mg and 
vitamin  E  (200mg/day)  plus  C.  vulgaris  in 
NAFLD  patients  as  a  supplement  (1200 
mg/day)  on  weight  and  serum  ALT  and 
AST levels in compared with control group 
(only metformin and vitamin E). They found 
statistically  significant  reduction  in  weight 
parallel to decreases in ALT and AST levels 
in  NAFLD  patients  after  consuming 
C.vulgaris. 
Mechanism underlying the improvement 
of  liver  enzymes  could  be  explained  by 
weight  loss  effects  of  C.  vulgaris.  Among 
adults  with  NAFLD  showed  significant 
changes  in  ALT  and  liver  histology  after 
weight loss.
27,28 Since weight loss in the C. 
vulgaris group was greater than the placebo 
group in the present study, it seems weight 
loss leads to decrease in hepatic triglyceride 
content  and  glyconeogenesis  which  even-
tually results in reduction in ALT concentra-
tion.
29  On  the  other  hand,  decline  in  liver 
enzymes  correlated  with  improvement  in 
insulin resistance.
30,31 
In the present study, FBS level decreased 
significantly in both group after at the end of 
the study. The change in FBS level was sta-
tistically significant between the two groups. 
Yuh et al. examined the effect of 100 mg/kg 
chlorella  consumption  on  streptozocin 
(STZ) induced diabetic mice and found hy-
poglycemic effect, enhanced and prolonged 
the hypoglycemic effects of exogenous insu-
lin  at  a  dose  which  does  not  produce  hy-
poglycemia in STZ mice.
12 Cherng et al. in 
another study reported a decrease in Non-
esterificated fatty acid (NEFA) level and en-
hanced  glucose  uptake  after  chlorella  con-
sumption  in  diabetic  mice.
19  Results  of  a 
study  on  diabetic  rats  for  the  effect  of  C. 
vulgaris on serum glucose level did not sup-
port the hypoglycemic effects of C. vulgaris,
11 
possibly due to short period of time. In a 
human  clinical  trial,  consumption  of  chlo-
rella  supplement  among  high-  risk  human 
subjects for lifestyle-related diseases resulted 
in  an  improvement  in  glucose  metabolism 
and  noticeable  reduction  in  serum  glucose 
level.
17 Chlorella enhances glucose uptake,
12 
decreases  NEFA  level
19  and  subsequently, 
lowers blood glucose. However, studies test-
ing the hypoglycemic effects of C. vulgaris are 
rare. Several mechanisms for hypoglycemic 
effects of C. vulgaris have been proposed, i.e. 
reduction  in  plasma  NEFA  concentration 
which improves glucose uptake, glucose uti-
lization, enhances the suppression of hepatic 
glucose production
19 as well as activation of 
insulin  signaling  pathways  results  from 
changes in gene expression in the peripheral Ebrahimi-Mameghani et al.: The Effect of Chlorella vulgaris … 
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blood  cells
17  are  the  possible  mechanisms. 
Chlorella consumption attenuated apoptosis 
and increased cell survival in pancreatic beta 
cells mediated by p53 down regulating.
32 
There  were  reductions  in  TC,  TG  and 
LDL-C  concentrations  not  only  in  the  C. 
vulgaris  but  also  in  placebo  group  with  no 
difference between the groups. Shibata et al. 
tested  three  different  chlorella  containing 
diets (0%, 5%, and 10% w/w) on hyperlipi-
demic rats and found lower TG and TC lev-
els in 5% and 10% groups vs. 0% group.
15 
Consumption of chlorella powder resulted in 
a significant decrease in serum and liver cho-
lesterol and TG in rats.
18 Finally, in a recent 
study by Panahi et al.
33 it was reported that, 
TC,  LDL-c  and  TG  are  reduced  in 
dyslipidemic  subjects  with  supplementation 
of 600 mg/day C. vulgaris. The hypolipidemic 
effect of C. vulgaris appears to be largely at-
tributable to its fiber content (i.e.13 g/100). 
Fiber causes high fecal steroid exertion as a 
consequence  of  the  reduction  in  intestinal 
absorption  Indeed,  C.  vulgaris  consumption 
has reported to enhance the hepatic degrada-
tion of cholesterol by up-regulation the ex-
pression  of  Cholesterol  7α  hydroxylase(the 
enzyme converts cholesterol to bile acids).
19 
TG lowering effects of C. vulgaris is possibly 
related  to  the  lowering  effect    in  plasma 
NEFA level because plasma NEFA is stored 
as TG in the liver.
22 C. vulgaris supplement 
contains niacin (23.8 mg/100g C. vulgaris or 
0.28 mg in 4 tablets) as a reputed medication 
for  hyperlipidemia  in  each  day  as  well  as 
Omega-3 fatty acids which may be responsi-
ble  for  the  hypotriglyceridemic  effects  of 
this microalgae.
33 
 As we tested the metabolic effects of C. 
vulgaris  on  relatively  low  sample  size,  with 
low dose and during short follow-up period, 
further long-term clinical trials are suggested.  
 
Conclusion 
 
Overall, 1200 mg C. vulgaris supplementa-
tion  compared  with  placebo  could  better 
decrease  weight,  serum  glucose  level  and 
improve lipid profile as well as liver functio-
nin  NAFLD  patients.  Further  studies  in 
human subjects are needed to investigate the 
mechanism  underlying  insulin  resistance, 
inflammation or oxidative stress in pathoge-
nesis of NAFLD. 
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